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Minimal change nephrotic syndrome (MCNS) is described as
a paraneoplastic manifestation of classical Hodgkin’s
lymphoma (cHL). We reassessed the pathophysiological and
clinical significance of this association. A retrospective study
was performed to evaluate a cohort of adult patients who
developed MCNS and cHL. Twenty-one patients recruited in
15 French centers were analyzed. cHL was associated with
inflammatory and general symptoms in most cases. The
morphological subtype was predominantly nodular sclerosis
(71.4%). MCNS appeared before the diagnosis of lymphoma
in eight patients (38.1%) and in this case, it was characterized
by a nephrotic syndrome (NS) frequently resistant (50%) or
dependent (12.5%) to steroid treatment. Interestingly,
diagnosis (3–120 months after MCNS) and effective treatment
of the hemopathy were associated with the disappearance of
the MCNS. cHL was diagnosed before MCNS in nine patients
(42.9%), and in this case, glomerulopathy was associated
with cHL relapse in 55.5% of cases. In four patients (19%), the
two diseases occurred simultaneously. Extensive
immunohistochemical study of lymph nodes was performed
in eight patients and did not reveal particular features. In
conclusion, MCNS associated with cHL is frequently
dependent or resistant to steroid regimen, but remission of
NS is obtained with the cure of lymphoma.
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Although it is well recognized that many types of
glomerulonephritis are associated with classical Hodgkin’s
disease (cHL), the incidence of nephrotic syndrome (NS) is
low and estimated at about 0.5 to 1%.1 In two largest
studies of 1700 Hodgkin’s disease patients, two glomerulo-
pathies were significantly associated with cHL, amyloidosis
(0.1% of cases) and minimal change nephrotic syndrome
(MCNS) (0.4% of cases).2,3 MCNS is a clinical and
pathological entity defined by selective proteinuria and hypo-
albuminemia that occurs in the absence of cellular glomer-
ular infiltrates or immunoglobulin deposits.4 Although
pathogenesis of MCNS is unclear, many observations
point to an immune origin.5 Currently, it is hypothesized
that MCNS is a consequence of immune cell dysfunction
that may lead to release of a glomerular permeability
factor.6
A close relationship between the courses of cHL and
MCNS has been reported in patients who suffer from both
diseases, particularly in that remission of MCNS occurs after
successful treatment of cHL, suggesting that MCNS is a
paraneoplastic syndrome in the context of cHL.7 The
pathogenesis of this association remains poorly understood
and the underlying molecular link is still unknown.
Alteration in T-lymphocyte functions that occurs in some
patients with cHL might be incriminated.5,7,8
Recent advances in pathophysiological understanding of
both diseases led us to reassess the significance of this
association, by revisiting clinical, histological, laboratory, and
therapeutic data. We conducted a retrospective study of 21
adult patients who developed both diseases. Patients were
separated into three groups, based on the interval between
onset of the two diseases (MCNS occurring before, after, or
simultaneously with cHL). The aim of this study was to
identify some features specific to this association, which may
provide new insights into the pathophysiology of these
diseases.
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RESULTS
The natural history of cHL and MCNS, including clinical,
histological, laboratory, and therapeutic characteristics, was
analyzed in 21 patients, 14 male and seven female patients.
MCNS characteristics
Clinical characteristics of MCNS at presentation are pre-
sented in Table 1.
The average age at diagnosis was 28.5 years (range 16–54
years). Every patient manifested all features of NS. A renal
biopsy was performed in 19 patients and histological
examination was not performed in one patient because of
anticoagulant therapy (pt5) and in another patient because of
remission of a pure NS within 5 days after the institution
of cHL treatment (pt2).
Results of kidney biopsy are listed in Table 2. Five patients
presented, on renal tissue biopsy, a minor interstitial infiltrate
(pt7, pt11, pt15, pt18, and pt21), whereas kidney biopsy
showed in two other patients (pt1 and pt19) an uncommon
intense inflammatory interstitial infiltrate during the course
of MCNS. In these two cases, immunophenotyping of this
infiltrate did not show lymphomatous infiltration but
revealed a T-cell reactive infiltrate mainly composed
of CD4þ and CD8þ T cells.
Response to treatment and outcome of MCNS are listed in
Table 3.
Initial treatment consisted in steroids in 18 patients.
Eleven patients received exclusively steroid treatment,
whereas steroids were included in chemotherapy in five
patients (pt2, pt4, pt14, pt16, and pt19). In the last two
patients (pt1 and pt3), steroid treatment was started in
parallel to chemotherapy.
Thirteen of 18 patients treated with steroids went into
remission (72.2%), whereas three (pt6, pt11, and pt15) were
steroid-resistant (16.7%) and two (pt8 and pt20) were
steroid-dependent (11.1%) after initial therapy.
Glomerular disease went into remission in all patients
treated simultaneously for the two diseases.
Two patients (pt7 and pt12) initially steroid-sensitive
became steroid-resistant, following a new episode of
MCNS relapse. Overall, five patients (pt6, pt7, pt11, pt12,
and pt15) were steroid-resistant and two (pt8 and
pt20) steroid-dependent (7/18¼ 38.8%). In six of these
seven patients, the effective treatment of cHL upon
diagnosis, established after 3–120 months of steroid
dependency or resistance, was associated with remission
of MCNS. The patient 15 was still in complete response
of cHL.
Three patients (14.3%) did not receive steroid therapy to
treat MCNS. Chemotherapy alone induced remission of
MCNS in two cases (pt13 and pt21). Spontaneous remission
of NS occurred in the last patient (pt17).
Cyclosporin A was started in four patients (pt7, pt11, pt12,
and pt15) because of steroid-resistant or -dependent NS, and
was ineffective in all cases.
Five patients (23.8%) (pt2, pt7, pt10, pt12, and pt18) had
MCNS relapse between 12 months and 10 years after the first
episode of NS.
None of the patients had progressed toward end-stage
renal failure at the end of the follow-up (mean follow-up 6.3
years).
We did not observe any correlations between the stage or
the subtypes of cHL and remission of NS (P¼ 1 and 0.26,
respectively). Moreover, the risk of relapse of MCNS was not
associated with the stage and subtypes of cHL (P¼ 0.47 and
0.53, respectively).
cHL characteristics
Clinical presentation, response, and outcome of cHL are
summarized in Table 4. Lymphoma was discovered during
management of steroid-resistant NS in two patients (pt6 and
pt11). In other cases, the diagnosis resulted from etiological
investigation of systemic symptoms such as prolonged fever
(pt9, pt13, and pt17) and peripheral lymphadenopathies
(n¼ 16), including four patients with simultaneous MCNS
(pt1, pt2, pt3, and pt4).
Table 1 | Baseline clinical characteristics of patients with MCNS
Patients
MCNS before cHL
(N=8)
MCNS and cHL
simultaneously (N=4)
MCNS after cHL
(N=9)
Total
(N=21)
Men/women Men: 6 Men: 4 Men: 4 Men: 14
Women: 2 Women: 0 Women: 5 Women: 7
Age at onset (years) 26.6 25 33.8 28.5 (range 16–54)
Mean delay 28.8 months (range 3–120
months)
59 months (range
2–156 months)
MCNS/cHL
cHL/MCNS
Urinary protein (g/day) 10.5 11.7 10.4 10.9 (range 3–30)
Serum albumin (g/l) 14 15.5 17.2 15.6 (range 7–28)
Lower than 20 g/l 7/8 4/4 7/9 18/21
Microscopic hematuria 2/8 1/4 1/9 4/21 (19%)
Renal insufficiency (4120mmol/l) 0/8 0/4 2/9 2/21 (9.5%)
Hypertension 1/8 2/4 0/9 3/21 (14.3%)
Thrombotic event 1/8 1/4 0/9 2/21 (9.5%)
cHL, classical Hodgkin’s lymphoma; Ig, immunoglobin; MCNS, minimal change nephrotic syndrome.
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Histological examination showed nodular sclerosis Hodg-
kin’s lymphoma in 15 cases (71.4%) and mixed cellularity in
five cases (23.8%). In one case, disease exclusively involved
bone marrow (pt7). Extensive immunohistochemical study
of lymph nodes was performed in eight patients and the
results are listed in Table 5 (see below).
Systemic symptoms (B) were noted in 15 cases (71. 4%).
Inflammatory markers were present (b) in 19 patients
(90.5%). Human immunodeficiency virus serology was
negative in all tested patients (n¼ 17).
The outcome for each patient is shown in Table 6. After
induction treatment, all patients were in remission. cHL
relapse occurred in five patients (pt13, pt14, pt16, pt19, and
pt20) within a period ranging from 15 months to 13 years.
One patient died because of septic shock during his second
lymphoma relapse (pt13).
Description MCNS and cHL according to the interval between
onset of the two diseases
Three groups of patients were defined according to the
interval between the onset of the two diseases.
MCNS and cHL occurring simultaneously. Four patients
(19%, pt1–pt4) presented cHL simultaneously with NS.
Nodular sclerosing subtype was found in four patients and
detailed immunohistochemical study was performed in two
patients (Table 5). We were unable to demonstrate T or B
immunophenotype of Hodgkin and Reed–Sternberg (HRS)
cells in these patients. The cellular infiltrate in lymphomatous
tissue contained no neoplastic inflammatory cells, as is
observed in cHL without MCNS.
Only one patient presented an inflammatory infiltrate in
the renal interstitium and no immunoglobulin (Ig)M deposit
was observed in the mesangium (Table 2).
All these patients were in complete remission from both
diseases after chemotherapy (containing steroids in two cases
or combined with a steroid-free regimen in the two others)
(Tables 3 and 4). In one patient, isolated NS recurred 10 years
later without evidence of cHL relapse (pt2) (Table 6). None
of the patients had cHL relapse in this subgroup.
MCNS preceding cHL (at least 2 months between the
occurrence of the two diseases). This population consisted
in eight patients (38.1%) (pt5–pt12). Median interval
Table 2 | Histological findings in 19 of 21 patients with MCNS at presentation
Patients Glomeruli Tubules Vessels Interstitium Immunofluorescence
MCNS before cHL (N=8) Normal 7/7 Normal 7/7 Normal 7/7 Normal 5/7 Negative 4/7
Seven kidney biopsies Interstitial infiltrate 2/7 IgM 3/7
MCNS and cHL
simultaneously (N=4)
Normal 3/3 Normal 3/3 Normal 3/3 Normal 2/3 Negative 3/3
Three kidney biopsies Interstitial infiltrate 1/3
MCNS after cHL (N=9) Normal 9/9 Normal 8/9 Normal 7/9 Normal 5/9 Negative 9/9
Nine kidney biopsies Necrotizing
tubulopathy 1/9
Endarteritis,
fibrosis: 2/9
Interstitial infiltrate 4/9
cHL, classical Hodgkin’s lymphoma; MCNS, minimal change nephrotic syndrome.
Table 3 | Treatment (initial and during relapse) and outcome of patients with MCNS
Patients
MCNS before cHL
(N=8)
MCNS and cHL
simultaneously (N=4)
MCNS after cHL
(N=9)
Total
(N=21)
Initial treatment with steroids 8/8 4/4 6/9 18/21
2/4 (included in
chemotherapy
3/6 (included in
chemotherapy
5/18 (included in chemotherapy)
2/4 (in parallel to
chemotherapy)
3/6 (without
chemotherapy)
11/18 alone
2/18 (in parallel to chemotherapy)
Initial steroid responsiveness Remission: 5/8 (62.5%) Remission: 4/4 (100%) Remission: 4/6 (66.6%) Remission: 13/18 (72.2%)
Resistant: 2/8 (25%) Resistant: 0/4 (0%) Resistant: 1/6 (16.7%) Resistant: 3/18 (16.7%)
Dependent: 1/8 (12.5%) Dependent: 0/4 (0%) Dependent: 1/6 (16.7%) Dependent: 2/18 (11.1%)
Initial treatment without steroids 0/8 0/4 3/9 3/21 (14.3%)
2/3 chemotherapy
without steroids
1/3 spontaneously
remission
Outcome during treatment without
steroids
Remission 2/2
Relapse 3/8 (37.5%) 1/4 (25%) 1/9 (11.1%) 5/21(23.8%)
Responsiveness to steroids during
relapse
Remission: 1/3 (33.3%)
Resistant 2/3 (66.7%)
Remission: 1/1 (100%) Remission 1/1 (100%) Remission 3/5 (60%)
Resistant 2/5 (40%)
Outcome of resistant or dependent
patients (initial or during a
relapse) with chemotherapy
Remission (5/5) No cHL relapse 1/2
Remission: 1/2
Remission: 6/7 corresponding to
100% of patients achieved
chemotherapy
cHL, classical Hodgkin’s lymphoma; MCNS, minimal change nephrotic syndrome.
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between the two diseases was 28.8 months (range 3–120
months) (Table 1).
Renal biopsy revealed inflammatory interstitial infiltrate
in two cases (pt7 and pt11) and IgM deposits in three
cases (pt5, pt9, and pt11). No correlation between these
findings and the time to onset of cHL (Table 2) or
steroid resistance was identified. Patients in this subgroup
showed a poor response to the steroid regimen as compared
to patients with MCNS alone (Tables 3 and 6). Thus, NS
was steroid-resistant at the first onset in two patients (pt6
and pt11), and steroid-dependent in one patient (pt8). It
was steroid-sensitive in five patients (pt5, pt7, pt9, pt10, and
pt12), but two of them experienced NS relapse (pt7 and
pt12) and became steroid-resistant (Table 6). Cyclosporin A
was given to three patients (pt11, pt12, and pt7) to control
the NS (Table 3), but failed to induce remission and
NS persisted up to the diagnosis of cHL, which was
made respectively 2.5 months, 15 months, and 6.5 years
after introduction of cyclosporin A. At cHL diagnosis,
cyclosporin A was discontinued. Interestingly, effective
treatment of cHL with chemotherapy was associated in all
cases with complete resolution of MCNS (Table 6). MCNS
relapse alone, without concomitant active cHL, occurred in
one patient (pt12).
Immunophenotyping of HRS cells did not reveal evidence
for a T-cell origin of the neoplastic cells (Table 5).
MCNS appearing in the course of cHL (at least 2 months
between the occurrence of the two diseases). Nine patients
fulfilled these criteria (42.5%) (pt13–pt21). The average
interval between the two diseases was 59 months (range
2–156 months).
Remission of cHL was seen in all patients following
chemotherapy. After induction treatment, five patients
(55.5%) experienced cHL relapse, which closely preceded or
occurred simultaneously with MCNS (pt13, pt14, pt16, pt19,
and pt20) (Tables 4 and 6). In three other patients (pt15,
pt17, and pt18), MCNS occurred without cHL relapse
(Table 6). In one patient (pt21), MCNS occurred between
the first and second course of chemotherapy, which resulted
in complete remission of NS.
In contrast to other subgroups, histological analyses of
lymph nodes showed a mixed cellularity but not a sclerosing
subtype in four patients (pt14, pt16, pt17, and pt19).
Extensive phenotyping was performed in two patients (pt20
and pt21) and did not reveal evidence for a T-cell origin of
HRS cells (Table 5).
Specific treatment of MCNS consisted in steroid therapy
in six patients. Steroid therapy was included within the
Table 4 | Clinical characteristics of patients with cHL at presentation
Patients
MCNS before cHL
(N=8)
MCNS and cHL
simultaneously (N=4)
MCNS after cHL
(N=9)
Total
(N=21)
Men/women Men: 6 Men: 4 Men: 4 Men: 14
Women: 2 Women: 0 Women: 5 Women: 7
Age at onset (years) 28.7 25 28 27.2 (range 17–65)
Clinical presentation Isolated lymph node
involvement: 5/8 (62.5%)
Lymph node
involvement associated
with NS: 4/4 (100%)
Isolated lymph node
involvement: 7/9 (17.7%)
Isolated lymph node
involvement: 12 (57.1%)
Isolated NS resistant to
steroids: 2/8 (25%)
Others: 2/9 (22.3%) Associated with NS: 4 (19%)
Others: 1/8 (12.5%) Isolated NS: 2 (9.5%) Others:
3 (14.3%)
Ann Arbor staging I: 1 I: 1 I: 1 I: 3 (14.3%)
II: 4 II: 1 II: 6 II: 11 (52.4%)
III: 2 III: 2 III:1 III: 5 (23.8%)
IV: 1 IV: 0 IV: 1 IV: 2 (9.5%)
WHO classification Nodular sclerosis: 7/8 Nodular sclerosis: 4/4 Nodular sclerosis: 4/9 Nodular sclerosis: 15 (71.4%)
Exclusive bone marrow
involvement: 1/8
Mixed cellularity: 5/9 Mixed cellularity: 5 (23.8%)
Exclusive bone marrow
involvement: 1 (4.8%)
Systemic symptoms A/B A: 2 A: 1 A: 3 A: 6 (28.6%)
B: 6 B: 3 B: 6 B: 15 (71.4%)
Inflammatory syndrome a/b A: 0 a: 0 a: 2 A: 2 (9.5%)
b: 8 b: 4 b: 7 b: 19 (90.5%)
Initial induction treatment
responsiveness
Complete remission: 8/8 Complete remission: 4/4 Complete remission : 9/9 Complete remission: 21
Relapse 0/8 0/4 5/9 5/21
cHL, classical Hodgkin’s lymphoma; MCNS, minimal change nephrotic syndrome; NS, nephrotic syndrome.
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chemotherapy regimen in three patients (pt14, pt16, and
pt19), with a complete remission of both diseases in all cases
(Table 6). In three others (pt15, pt18, and pt20), exclusive
steroid therapy was initiated without chemotherapy, but only
one patient (pt18) achieved a complete response (Table 6).
One patient (pt20) was steroid-dependent, whereas another
(pt15) was steroid- and cyclosporine-dependent (Table 6).
Interestingly, in the first case (pt20), successful treatment of
cHL relapse (13 months after the onset of MCNS) was
associated with complete remission of NS. Among the last
three patients, one presented spontaneous remission of
MCNS (pt17) and the two others (pt13, pt21) were
successfully treated by chemotherapy without steroids, with
complete remission of both diseases.
DISCUSSION
In this retrospective French survey, we have identified 21
adult patients who presented both MCNS and cHL. Although
there are strong suggestions of a link between MCNS
and cHL, only small-scale studies have been published
and do not provide a clear picture with respect to diagnosis,
outcome, and treatment. Furthermore, no extensive studies
of the pathological features of this association have been
performed.
We deliberately excluded patients suffering from nodular
lymphocyte-predominant Hodgkin’s lymphoma (HL), which
represents approximately 5% of all cases of Hodgkin’s disease,
as these two entities do not have an identical molecular
basis.9 Moreover, pediatric cases of this association have been
described, but we exclusively studied patients older than 16
years.10
Temporal relationship between onset of NS and cHL
In the largest reported meta-analysis, Eagen and Lewis11
noted that 12 out of 26 patients had cHL and MCNS
simultaneously, whereas NS preceded lymphoma in three
cases and manifested after lymphoma in 11 cases. In only five
cases, the interval between the occurrence of the two diseases
was above 12 months. By contrast, our results indicate a
median time of 15 months (range 0–156). Only four patients
(19%) concurrently developed MCNS and cHL. Nevertheless,
five additional patients simultaneously experienced cHL
relapse and NS. The longest between-disease interval
reported in the literature is 42 months.12 Here, we report
two patients, in whom the interval was 120 and 156 months,
suggesting that this association may appear with a long lag
time. This discrepancy is likely owing to the fact that previous
reports are based on small series, which in most cases report
Table 5 | Immunohistochemical study of lymphomatous tissue from eight patients
Patients Type CD30 CD15 CD20 CD3 CD8 TiA1 LMP EBER
HRS cells: , negative; +, positive
MCNS before cHL
Pt6 NS + +      
Pt8 NS + +     + +
Pt9 NS + +      
Pt10 NS + +      +
MCNS and cHL simultaneously
Pt1 NS + +      
Pt3 NS + +      
cHL before MCNS
Pt20 NS + +     + +
Pt21 NS + +      
Patients CD20 CD3 CD8 TiA1 Granzyme CD15
Cellular background: , no cellular subset stained; +, cellular subset stained present
MCNS before cHL
Pt6 + + + +  +
Pt8 + + + + + +
Pt9 + + +   +
Pt10 + + + +  
MCNS and cHL simultaneously
P1 + + + +  
P3 + + + + + 
cHL before MCNS
P20 + + + + + +
P21 + + + + + +
cHL, classical Hodgkin’s lymphoma; HRS, Hodgkin and Reed–Sternberg; MCNS, minimal change nephrotic syndrome; NS, nodular sclerosis subtype.
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only concomitant cases. One could also argue that in such
cases, MCNS and cHL are not related. However, although not
present at diagnosis of cHL 156 months earlier (pt14), the
occurrence of MCNS concomitantly with cHL relapse
strongly suggests a link between the two diseases. In this
case, it is reasonable to hypothesize that either MCNS was
not diagnosed at the first occurrence of cHL or that the
biology of the tumor cells may have changed during relapse.
In another case (pt7), MCNS occurred 120 months before the
onset of cHL. Interestingly, in this patient, MCNS only
resolved with chemotherapy of cHL, suggesting a link
between the two diseases.
Of note, MCNS that occurred a long time before cHL is
usually resistant to and/or dependent on steroid or cyclospor-
ine therapy. This observation raises two questions. First,
should investigations to search for cHL be performed in
therapy-resistant MCNS? Second, is cHL occurring after a long
history of resistant MCNS related to immunosuppression?
Table 6 | Outcome of 21 patients with MCNS and cHL
Start
follow-
up
(years)
Interval
between the
two diseases
(months) MCNS remission
cHL
remission
Outcome of
MCNS with
chemotherapy
MCNS relapse
(delay in months
after the first
episode of MCNS)
cHL relapse
(delay in months
after the first
episode of cHL)
End of
follow-up
(years)
MCNS and cHL occurring simultaneously
Pt1 1990 0 Yes Yes Complete
remission
No No 2000
Pt2 1990 0 Yes Yes Complete
remission
Yes (120) No 2002
Pt3 1999 0 Yes Yes Complete
remission
No No 2002
Pt4 1999 0 Yes Yes Complete
remission
No No 2002
MCNS before cHL
Pt5 1997 10 Yes Yes Not done No No 2002
Pt6 1995 3 Steroid resistance (for
3 months)
Yes Complete
remission
No No 2002
Pt7 1991 120 Steroid and cyclosporine
resistance after the
relapse (for 84 months)
Yes Complete
remission
Yes (36) No 2002
Pt8 1999 7 Steroid dependence
(for 7 months)
Yes Complete
remission
No No 2002
Pt9 1995 30 Yes Yes Not done No No 2002
Pt10 1999 25 Yes Yes Not done Yes (16) No 2002
Pt11 2001 5 Steroid and cyclosporine
resistance (for 5 months)
Yes Complete
remission
No No 2002
Pt12 1998 29 Steroid and cyclosporine
resistance after the
relapse (for 18 months)
Yes Complete
remission
Yes (11) No 2002
cHL before MCNS
Pt13 1986 15 Yes Yes Complete
remission,
No Yes (15) 1990
Pt14 1973 156 Yes Yes Complete
remission
No Yes (156) 1987
Pt15 1977 104 Steroid and cyclosporine
resistance
Yes Not done no No 1998
Pt16 1983 39 Yes Yes Complete
remission
No Yes (39) 1990
Pt17 1984 17 Yes Yes Not done No No 1988
Pt18 1989 67 Yes Yes Not done Yes (78) No 2002
Pt19 1985 104 Yes Yes Complete
remission
No Yes (104) 1998
Pt20 1997 30 Steroid dependence
after the relapse
(for 13 months)
Yes Complete
remission
No Yes (43) 2002
Pt21 2002 2 Yes Yes Complete
remission after
the second
course of
chemotherapy
No No 2002
cHL, classical Hodgkin’s lymphoma; MCNS, minimal change nephrotic syndrome.
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Risk factors for development of MCNS during the course
of cHL
It has been reported that MCNS is more frequently associated
with cHL exhibiting a mixed cellularity histological sub-
type.13 In contrast, our study shows that the nodular
sclerosing subtype is predominant (71.4%). In order to
shed light on pathophysiology of this association, immuno-
histochemical examination of lymph node tissue biopsy
specimens was extensively performed in eight patients.
Although HRS cells seem to derive from germinal center B
cells,14 studies of T-cell receptor-b and Ig gene rearrange-
ments of micro-manipulated HRS cells in cHL suggest
that, in rare cases, HRS cells may derive from T cells.15,16
Our immunohistochemical analysis suggests that cHL tumor
cells do not exhibit a T-cell phenotype. Moreover, no excess
of reactive T cells was observed when compared to cHL
without MCNS (Table 5 and data not shown). It has been
reported that Epstein–Barr virus is present in the lesions of
about 40% of cHL cases,17,18 a frequency that is similar to
ours (37.5%).
As in other studies, we were not able to identify a
particular subgroup of patients at high risk of MCNS, with
respect to age, sex, or stage of the disease. In contrast,
systemic symptoms were found in approximately 72% of
cases, a frequency higher than that observed in cHL without
MCNS (40% of cases).17 Furthermore, cHL with MCNS is
also characterized by high prevalence of inflammatory
syndrome, which was present in 90.5% of case. Both these
findings were not previously reported and may result from an
excessive production of inflammatory cytokines. Several
reports have shown that patients with B symptoms had
higher serum interleukin (IL)-6 levels than asymptomatic
patients.19 A possible link between the presence of B
symptoms and MCNS is hard to establish. First, in contrast
to amyloidosis, MCNS is not a kidney disease associated with
inflammation. Second, the serum level of IL-6 is normal in
classical MCNS,6 and it has been demonstrated that
prolonged overexpression of IL-6 in transgenic animal leads
to glomerulonephritis histologically characterized by mesan-
gial proliferation.20
Inflammatory status is a poor predictor of cHL in MCNS
patients because, in most cases, MCNS, regardless of its
etiology, is associated with disturbance of inflammatory
proteins.
Characteristics and treatment of MCNS associated with cHL
The characteristics of cHL-associated MCNS do not differ
from those of classical glomerular disease. An interstitial
infiltrate was observed in seven patients and was apparently
neither associated with the risk of developing cHL nor with
steroid resistance.
In our study, NS recurred in five cases and was predictive
of cHL relapse in three cases (pt7, pt10, and pt12) with
potentially long intervals (9, 102, and 7 months, respectively).
Therefore, patients with NS and a history of cHL should be
investigated for lymphoma relapse.
Effective treatment of cHL is generally associated
with simultaneous remission of NS whatever the therapeutic
strategy, which included chemotherapy, field irradiation,
and lymph node surgery, thus confirming the paraneo-
plastic nature of this glomerulopathy.2,21–24 As in our study,
100% of patients efficiently treated for HL in Eagen’s
study were also in remission from NS.11 Moreover, in our
study, all patients treated by chemotherapy for MCNS
(when the two diseases occurred simultaneously, during
a cHL relapse or in patient with steroid-dependent or -
resistant NS) went into remission of NS after successful
treatment of Hodgkin’s disease whatever the type of
chemotherapy regimen used, and even if steroids were
not used. In fact, as previously described by others, our
findings suggest that MCNS remission is rather conditioned
by the response of lymphoma to chemotherapy than by the
type of treatment proposed for cHL. Therefore, the prognosis
of MCNS seems to be directly related to the prognosis of
cHL. Likewise, Stephan et al.10 described a case where
ineffective chemotherapy for cHL was associated with
persistence of proteinuria.
We observed that patients who presented with MCNS
preceding cHL displayed a high frequency of steroid
resistance (50%). To our knowledge, our study reports the
first cases of cyclosporine-resistant NS preceding cHL.25 We
could hypothesize that HRS or environmental tumor cells
may secrete a glomerular permeability factor before the onset
of cHL. The resolution of MCNS after cHL treatment
emphasizes this hypothesis.
When MCNS occurs after cHL, steroids constitute the first
line of treatment after excluding the HL relapse. Nevertheless,
even in the absence of cHL relapse, chemotherapy (MOPP
regimen) led to the remission from recurrent MCNS in
patients with a history of cHL associated with steroid-
resistant MCNS.26
Pathogenic hypothesis
T-cell function similarities between the two diseases. Our
extensive immunohistochemical study of lymphomatous
tissues was performed in eight patients in order to investigate
whether or not a T-cell origin of HRS cells was associated
with MCNS. We failed to demonstrate HRS expression
of markers that are typical for T cell. Therefore, although
we did not perform an analysis for Ig and T-cell receptor
rearrangements, it is likely that in our group of patients, no
special origin of HRS is associated with MCNS. However, it
remains to be determined whether tumor cells and/or
infiltrating cells including T cells may produce a putative
circulating factor that impairs the glomerular filtration
barrier.
In agreement with the hypothesis of T-cell impairment,
many similarities concerning T-cell function during the two
diseases have been documented. Clinical observations and
experimental data suggest that both diseases are associated
with an expansion of T cells polarized towards a Th2 pheno-
type.6,14 This might explain why patients with MCNS and
Kidney International (2006) 69, 2251–2260 2257
V Audard et al.: Minimal change NS and cHL o r i g i n a l a r t i c l e
Hodgkin’s disease often exhibit a defect in delayed-
type hypersensitivity response, suggesting an abnormal
Th1-dependent cellular immunity.6,27 Moreover, it has
recently been shown that T lymphocytes from MCNS display
downregulation of the IL-12 receptor b2 subunit during
relapse, suggesting that T cells of MCNS are driven early
towards a Th2 phenotype.28
Role of cytokines. Some clinical and histopathological
features, characteristics of cHL, have been linked to an
abnormal production of cytokines.29
Th2 cytokines seem to be involved in both
diseases, particularly IL-13. In situ hybridization has shown
that IL-13 and its receptor (IL-13-Ra1) are constitutively
expressed by HRS cells.30 Furthermore, neutralization
of anti-IL-13 antibody inhibits proliferation of the Hodgkin’s
disease-derived cell line HDLM-2.29 Yap et al.31
have demonstrated increased production of IL-13 mRNA
in T lymphocytes of patients with MCNS during MCNS
relapse. Interestingly, the IL-4 and IL-13 receptors are
expressed by podocytes in various glomerular diseases,
raising the possibility that IL-13 might contribute to the
pathophysiology of proteinuria.32 Van Den Berg et al.32 have
demonstrated that IL-4 and IL-13 increase transcellular ion
transport, but they do not affect the permeability to
macromolecules.
Role of NF-kB overexpression. Most cytokines whose levels
are thought to be increased during active MCNS and cHL
and downregulated during remissions are partly or pre-
dominantly regulated by the nuclear factor-kB (NF-kB)
proteins.33
During MCNS relapses, peripheral mononuclear cells,
including T cells, exhibit high NF-kB binding activity, which
returns to basal levels during remissions.34
Consistent NF-kB overexpression in HRS cells in cHL
lymph nodes has also been reported.35,36 Several mechanisms
have been implicated in this constitutive activation: clonal
deleterious mutations in the IkBa gene, and constitutive
stimulation of receptors such as CD40, RANK, and
LMP1.14,17,37–39
As HL is associated with upregulation of NF-kB,
independently of kidney disease, an additional as yet
undetermined mechanism may explain the cooccurrence of
MCNS.
Conclusion
Our study confirms the link between MCNS and cHL, and
strongly suggests that chemotherapy is the best treatment of
MCNS associated with cHL. Although rare and still
unexplained, this association may shed light on the
pathophysiology and treatment of both diseases.
MATERIALS AND METHODS
Patient population
Twenty-one patients older than 16 years of age suffering from cHL
and MCNS were identified and followed between 1973 and 2004 in
15 nephrology and hematology centers at French hospitals.
cHL characterization
All patients underwent a histological study of the lymph nodes or
extranodal lesions to confirm the diagnosis of cHL. The diagnosis of
cHL required the finding of HRS cells in an appropriate cellular
background of reactive leukocytes, histiocytes, and in some cases
fibrosis.40 The histological subtypes were defined according to the
WHO classification of HL (nodular sclerosis, mixed cellularity,
lymphocyte-rich, and lymphocyte-depleted cHL).41 The modified
(Cotswolds revision) Ann Arbor staging system was detailed for each
patient.42 Systemic symptoms at presentation consisting in fever,
weight loss, and night sweats were recorded (A: absence/B:
presence).
Laboratory parameters of inflammatory syndrome including
C-reactive protein, sedimentation rate, and fibrinogen levels were
assessed (a: absence/b: presence).
Treatment of HL was, in most cases, based on combined
treatment with radiotherapy and classical chemotherapy of cHL.43
The first-line chemotherapy regimen used in our patients
included ABVD regimen (adriamycin, bleomycine, vinblastine,
dacarbazine) in nine patients (pt2, pt3, pt4, pt5, pt6, pt12, pt13,
pt17, and pt21), MOPP regimen (mechloretamin, oncovin,
procarbazin, prednisone) in three patients (pt15, pt16, and pt19),
MOPP/ABV regimen in four patients (pt1, pt9, pt11, and pt18), and
BEACOPP regimen (bleomycin, doxorubicin, cyclophosphamide,
vincristine, procarbazin, prednisone, gencitabizine) in two patients
(pt7 and pt8). OPPA regimen (oncovin, prednisone, procarbazin,
doxorubucin) and EBVP regimen (epirubicin, bleomycin, vinblas-
tine, prednisone) were started in two patients (pt10 and pt20,
respectively). The last patient received Velbe alone for the treatment
of cHL (pt14).
Partial remission was defined by persistence of tumor mass and/
or clinical and/or laboratory symptoms after induction therapy.
Relapse was confirmed by histological examination.
Eight patients with biopsy-proven cHL were extensively reviewed
histologically to characterize the immunophenotype of HRS and
background cells. Lymph nodes were fixed in 4% formaldehyde or in
Bouin solution.
Immunohistochemistry was performed for all the antigens using
the avidin–biotin technique after antigen retrieval with monoclonal
antibodies against CD3 (1/250), CD20 (1/200), CD15 (1/50), CD8
(1/200), from Dakocytomation (Trappes, France), CD30 (1/50),
TiA1 (1/100) from Immunotech (Marseille, France), and Granzyme
(1/50) from Monosan (Perrayen yvelines, France). Epstein–Barr
virus was detected in paraffin-embedded sections by immunohis-
tochemistry using a monoclonal anti-latent membrane protein1
antibody and/or by in situ hybridization with fluorescein isothio-
cyanate-labeled EBV RNA -specific oligonucleotides.
Characterization of minimal change NS
Diagnostic criteria for MCNS were based on clinical and laboratory
symptoms and in most cases on results of histological examination
of kidney specimens.
NS was clinically defined by urinary protein above 3 g/24 h
and serum albumin below 30 g/l. Histologically, MCNS was
defined by the presence of minimal change glomerular lesions
and absence of segmental sclerosis by optical microscopy,
negative immunofluorescence, or presence of IgM deposits
in the mesangium.44 Although MCNS therapy for children is
well standardized,13 there is no consensus for treatment in adult
patients. However, most were treated according to the protocol of
Glassok.45
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Complete remission was defined by the return of urine protein to
the normal range of less than 0.3 g/24 h, and relapse as reappearance
of proteinuria for more than 1 week. Steroid dependence was
defined as proteinuria relapse when the steroid dose was tapered.
Steroid resistance was defined as the persistence of NS after an
average of 10 weeks of prednisolone or prednisone treatment (range
8–12 weeks) at 1 mg/kg/day. Initial steroid treatment consisted in
oral prednisolone or prednisone (1 mg/kg/day) or intravenous
pulses of methylprednisolone (when included in the chemotherapy).
Impaired renal function was defined as a serum creatinine level
exceeding 120 mmol/l.
Statistical analysis
In order to compare clinical data and outcome of renal disease,
statistical analysis was performed using the Fisher’s exact test for
categorical data and the Mann–Whitney test for non-parametric
variables. A P-value o0.05 was considered statistically significant.
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